Cisplatin/Apo-Transferrin Adduct: X-ray Structure and Binding to the Transferrin Receptor 1

Area of Science:

• Biochemistry
• Structural Biology
• Medicinal Chemistry

Background:

• Cisplatin is a widely used anticancer agent for solid tumors.
• Human serum transferrin (hTF) is a key iron-transport protein.
• Understanding drug-protein interactions is crucial for developing targeted therapies.

Purpose of the Study:

• To determine the X-ray structure of the cisplatin-hTF adduct.
• To investigate how cisplatin binding affects hTF's structure and function.
• To explore the potential of hTF as a nanocarrier for cisplatin delivery.

Main Methods:

• X-ray crystallography to determine the adduct structure.
• In solution studies to assess protein conformation and receptor binding.
• Analysis of platinum binding sites within hTF.

Main Results:

• The X-ray structure of the cisplatin-hTF adduct was elucidated.
• Two platinum binding sites were identified in both N- and C-lobes of hTF.
• Cisplatin binding did not significantly alter hTF conformation or its ability to bind iron or transferrin receptor 1 (TfR1).

Conclusions:

• hTF maintains its structural integrity and biological functions after cisplatin binding.
• hTF can be utilized as a nanocarrier for targeted delivery of metallodrugs like cisplatin.
• This opens avenues for novel combination therapies in cancer treatment.